The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5 + cells in an amount effective to treat the S. aurreus infection in the subject.USO DE UNA COMPOSICIÓN QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINA C-C TIPO 5 (CCR5) PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR UNA INFECCIÓN POR STAPHYLOCOCCUS AUREUS, DONDE DICHA INFECCIÓN POR S. AUREUS ES CAUSADA POR UNA CEPA DE S. AUREUS QUE EXPRESA LukE/D.
